Navigation Links
Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
Date:10/18/2007

der HCV Patients

Schering-Plough also reported top line results from a completed Phase II study evaluating boceprevir dose response and the need for ribavirin in patients chronically infected with HCV genotype 1 who were nonresponders to previous peginterferon and ribavirin combination therapy (i.e., patients who did not have undetectable HCV-RNA or who did not achieve a 2 log decline in viral load with a minimum of 12 weeks of peginterferon and ribavirin combination therapy). These "null" nonresponders to peginterferon and ribavirin combination therapy represent the most difficult-to-treat patient population. Patients who relapsed following previous HCV therapy (relapsers) were not included in this study.

This study was complex, involving seven different treatment arms. Patients were initially randomized to low doses of boceprevir (100, 200, 400 mg TID) before initiating an 800 mg TID boceprevir arm. Under the study protocol, patients received these boceprevir doses in combination with PEGINTRON (1.5 mcg/kg weekly) with or without REBETOL (800-1400 mg daily) for 24 or 48 weeks, or received PEGINTRON and REBETOL alone as a control. During the ongoing review of the study by the Data Safety Monitoring Board (DSMB), it was recommended that patients in the lower-dose boceprevir arms who demonstrated a substantial antiviral response during treatment cross over to boceprevir 800 mg TID in combination with PEGINTRON and REBETOL for an additional 24 weeks. Patients who did not demonstrate a substantial antiviral response during treatment were discontinued from the study. In addition, patients in the control arm who did not respond to PEGINTRON and REBETOL alone were allowed to cross over to boceprevir 800 mg TID in combination with PEGINTRON and REBETOL. Patients received a maximum of 24 weeks of the optimized regimen (boceprevir 800 mg TID in combination with PEGINTRON and REBETOL). In all, 357 patients were enrolled at centers in the United States and Europe,
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
2. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
5. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
6. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
7. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Sygnis Pharma AG announces date for presentation of clinical results
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 ,, Reportlinker.com announces ... available in its catalogue: ,, Hepatitis ... Forecasts to 2015 ,, http://www.reportlinker.com/p0167309/Hepatitis-B-Vaccines---Pipeline-Analysis-and-Market-Forecasts-to-2015.html ... Analysis and Market Forecasts to 2015 ,, ... analysis specialist,s new report, "Hepatitis B Vaccines ...
(Date:12/15/2009)... Mass., Dec. 15 /PRNewswire-FirstCall/ ... today announced that SDMS Vision Publisher(TM) (v.7.1 SR4), ... Scientific Data Management System (SDMS), a secure electronic ... scientific data to a centralized database and is ... has been certified compliant with the SAFE-BioPharma digital ...
(Date:12/15/2009)... DIEGO, Dec. 15 Safe Life ... developing novel technologies that prevent the spread of ... ramping production of its comfortable, breathable, A400 Series ... address the global shortage of N95 respirators during ... capacity in response to a rapid rise in ...
Breaking Medicine Technology:Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 7Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 2Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 3Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 4Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 5Waters SDMS Vision Publisher Now Certified Compliant with SAFE-BioPharma Digital Standard 6Safe Life Ramps Production Capacity of Comfortable, Breathable N95 Respirator Amid Worldwide Shortage 2Safe Life Ramps Production Capacity of Comfortable, Breathable N95 Respirator Amid Worldwide Shortage 3Safe Life Ramps Production Capacity of Comfortable, Breathable N95 Respirator Amid Worldwide Shortage 4Zargis Cardioscan 28TM 29 Featured on The Early Show on CBS 6515 1Zargis Cardioscan 28TM 29 Featured on The Early Show on CBS 6515 2Zargis Cardioscan 28TM 29 Featured on The Early Show on CBS 6515 3Chronic Pain Trips Up Seniors 62056 1Chronic Pain Trips Up Seniors 62056 2Chronic Pain Trips Up Seniors 62056 3Hard To Treat Diseases 28HTDS 29 Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 62052 1Hard To Treat Diseases 28HTDS 29 Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 62052 2Hard To Treat Diseases 28HTDS 29 Exploration Of A 25 Billion Dollar Industry Regenerative Medicine and Stem Cell Bank Targeted Merger 62052 3
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
... Mass. and NEW YORK, March 20 ... and Nature Publishing Group (NPG) , a ... partnership to facilitate greater scientific collaboration and open ... together to stimulate the involvement of scientists worldwide ...
Other Medicine Technology:Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation 2InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation 3InnoCentive and Nature Publishing Group Announce Partnership to Facilitate Open Innovation 4
(Date:12/15/2009)... can help older adults delay or reverse declining ... researchers at the Johns Hopkins Bloomberg School of ... the researchers found that seniors participating in a ... regions that support cognitive abilities important to planning ... the first of its kind to demonstrate that ...
(Date:12/15/2009)... developmental changes increases risk in teens, study suggests , , ... overweight or obese increases the risk of obstructive sleep ... true for younger children, Australian researchers have found. , ... 2 to 18, who were referred for evaluation of ... that among those aged 12 and older the risk ...
(Date:12/15/2009)... today launches SafeConsole 4.0, the web management software for SafeStick, ... provide better usability for employees and more control for administrators ... options. , ... Washington, DC (PRWEB) ... provider of secure USB devices, today launches SafeConsole 4.0, the ...
(Date:12/15/2009)... a surgical method, with fewer complications, analysis finds, , , ... to diagnosing breast cancer, women and their doctors have ... invasive "core needle biopsy" procedure is nearly as effective ... is, with fewer complications than the surgical version. , ... 5 issue of Annals of Internal Medicine , ...
(Date:12/15/2009)... Virtual Health Technologies, Inc. (OTC Bulletin Board: VHGI) ... operating subsidiary of VHGI) has appointed two key ... assist with bringing the Treasure Gulch and Zero ... possible. Additionally, the company is informing interested shareholders ... a Live Investor Town Hall Meeting so that ...
Breaking Medicine News(10 mins):Health News:For older adults, participating in social service activities can improve brain functions 2Health News:Puberty May Trigger Sleep Apnea in Overweight Kids 2Health News:BlockMaster Launches SafeConsole 4.0 To Enhance Usability and Security of USB Devices 2Health News:BlockMaster Launches SafeConsole 4.0 To Enhance Usability and Security of USB Devices 3Health News:Needle Biopsy Works Well in Diagnosing Breast Cancer 2Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 2Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 3Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 4Health News:VHGI: VHGI Gold Taps Key Mining Professionals to Assist With Development Plan for $50,000,000 Potential Reserves at Treasure Gulch Gold Mine; Investor Town Hall Meeting to be Scheduled 5
... Oct. 15 Highlands Acquisition Corp.,(Amex: HIA.U), (the ... initial public offering have exercised in full their,over-allotment ... As,a result, the Company sold an additional 1,800,000 ... common stock and one warrant to purchase one,share ...
... Workers and their supporters to travel by caravan from Toledo, ... equity takeover of nation,s largest nursing home chain; Wash., ... Nursing home workers and,their supporters from across the nation ... improved care at the nation,s largest,nursing home chain as the ...
... 266,604 fewer patients would die annually, survey finds , ... top-ranked hospitals in the United States are 71 percent ... hospitals, according to a new study from the health-care ... Quality in America Study looked at 41 million Medicare ...
... Research asked a number,of questions to measure awareness of ... Trax(TM) survey. The study was conducted,with a national sample ... or read some kind of negative comments about Medicare ... a high of 28.8% for those with,MediGap coverage, to ...
... UV with Mexoryl(TM) SX, NEW YORK, Oct. 15 ... Revitalift UV Daily Moisturizing Cream,with Mexoryl SX (ecamsule), a ... both short and long UVA rays -- the number,one ... testing, the,revolutionary Mexoryl SX technology, exclusive to L,Oreal, has ...
... expands Apria,s national infusion footprint,and adds broad network ... Adds strength in fast-growing specialty pharmacy services ... payor and,product mix, Creates the premier specialty ... 15 Apria Healthcare Group,Inc. ("Apria Healthcare" or ...
Other Medicine News:Health News:Highlands Acquisition Corp. Announces Exercise of Over-Allotment Option 2Health News:Nursing Home Workers From Across the Nation to Rally in for Improved Nursing Home Care 2Health News:America's Top Hospitals Are Real Lifesavers 2Health News:Video: New FDA-Approved Sun Protectant Saves Skin All Year Round 2Health News:Apria Healthcare Signs Definitive Agreement to Acquire Coram, Inc. 2Health News:Apria Healthcare Signs Definitive Agreement to Acquire Coram, Inc. 3Health News:Apria Healthcare Signs Definitive Agreement to Acquire Coram, Inc. 4
... is based on sequential binding of HCG ... (specific for the *-chain of HCG) immobilized ... for the *-chain of HCG) conjugated to ... step, chromogenic substrate is added and colors ...
For the quantitative determination of Glycohemoglobin in blood....
... storage protein for iron. The ferritin molecule ... of heavy and light subunits, which surrounds ... phosphate [1]. Ferritin is synthesized in the ... with major concentrations found in the liver, ...
...
Medicine Products: